Targeting specific vulnerabilities in HPV-negative head and neck cancer
Project 2: Synthetic Lethal Therapy for HPV-Negative Head and Neck Cancer
This study is exploring a new way to treat HPV-negative head and neck cancers by using a mix of drugs that target specific parts of the cancer cells, especially those with certain gene changes, to help kill the cancer while keeping healthy cells safe.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10889238 on NIH RePORTER |
What this research studies
This research investigates a novel treatment approach for HPV-negative head and neck squamous cell carcinomas (HNSCC) that have lost critical cell cycle checkpoints. By using a combination of drugs that inhibit specific kinases involved in cell division, the study aims to exploit the unique vulnerabilities of these cancer cells, particularly those with mutations in the TP53 gene. The methodology involves testing these drug combinations in laboratory models to determine their effectiveness in inducing cancer cell death while minimizing harm to normal tissues.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with HPV-negative head and neck squamous cell carcinoma, particularly those with mutations in the TP53 gene.
Not a fit: Patients with HPV-positive head and neck cancers or those without the specific genetic mutations targeted by this research may not benefit.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted therapies for patients with HPV-negative head and neck cancer.
How similar studies have performed: Previous research has shown promise in using synthetic lethal strategies in cancer treatment, indicating potential for success in this approach.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Burtness, Barbara — Yale University
- Study coordinator: Burtness, Barbara
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.